The cost-effectiveness of transcatheter aortic valve implantation (TAVI) vs. surgical aortic valve replacement (SAVR) has previously been reported across the spectrum of surgical mortality risk. Earlier analyses relied on shorter-term trial data, with inherent uncertainty about lifetime survival projections. Recently presented 4-year follow-up data from the Evolut Low Risk Trial showed a maintained numerical survival benefit with TAVI. Based on these data, we present updated analyses for a European and United States context and discuss the implications for TAVI.
